Loading
Adding cetuximab to platinum and fluorouracil lengthened survival in recurrent or metastatic head and neck cancer from 7.4 to 10.1 months, the first improvement in first-line treatment in decades.
Phase 3 trial of 442 patients with untreated recurrent or metastatic head and neck squamous cell carcinoma randomised to cisplatin or carboplatin plus fluorouracil for up to six cycles, with or without cetuximab continued as maintenance.
Median overall survival was 10.1 versus 7.4 months (hazard ratio 0.80), progression-free survival 5.6 versus 3.3 months and response 36 versus 20 percent, with skin reactions and infusion reactions as the added toxicities.
EXTREME was the first-line standard for a decade and remains the option for patients unsuitable for pembrolizumab; it was the comparator that KEYNOTE-048 improved upon.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Cetuximab.
Shares Cetuximab, New England Journal of Medicine.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Cetuximab.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Cetuximab.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, New England Journal of Medicine.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Cetuximab.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Cetuximab.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Cetuximab.